Medical Condition News

RSS

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

17 Jul 2010

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

Cancer and stem cell biology researchers at the University of Colorado are launching the nation's first program focused on identifying and testing drugs that target and destroy cells thought to be at the root of cancer-cancer stem cells (CSCs).The Cancer Stem Cell-Directed Clinical Trials Program (CCTP) is a collaboration between the University of Colorado Cancer Center and the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, both located at the University of Colorado School of Medicine.

17 Jul 2010

AMPK may regulate epigenetic mechanism: Research

AMP-activated protein kinase, or AMPK, is a master regulator protein of metabolism that is conserved from yeast to humans. When a cell is low on fuel, AMPK shuts down processes that use energy and turns on processes that produce energy.Biologists have been studying how AMPK works for several decades and know that once it is activated, AMPK turns on a large number of genes by passing the "make more energy" message through numerous signaling cascades in the cell. What was not known, until now, was that AMPK also works via an epigenetic mechanism to slow down or stop cell growth.

17 Jul 2010

Proton therapy treatment for anal canal cancer performed for first time in US

The INTEGRIS Cancer Institute of Oklahoma and the ProCure Proton Therapy Center announce a breakthrough treatment approach for anal canal cancer. For the first time in the United States proton therapy is now being used to treat this type of cancer.

17 Jul 2010

Ingen files patent to produce new drug insulin thermos product

Ingen Technologies, Inc. (Pink Sheets:IGNT), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company has also filed a U.S patent and will begin the required manufacturing processes to produce the new drug insulin thermos product.

17 Jul 2010

Resveratrol concentration impacts cancer risk mitigation: Study

Agricultural Research Service (ARS) chemist Thomas Wang, who specializes in cancer prevention research, has reported evidence that for some dietary compounds, length of exposure over time may be key to whether or not ingestion leads to a beneficial, or detrimental, effect.Scientists do not know exactly why one person develops cancer and another does not. But they do know that certain nutrients might increase or decrease cancer risk. There are "layers" of factors involved in the development of cancer, and Wang is studying the layers involving peoples' diet complexity and gene expression.

17 Jul 2010

Pacific Shore releases clinical trial results for Burner Balm lip balm

Pacific Shore Holdings, Inc., today announced the release of the highly anticipated clinical trial results for Burner Balm lip balm. According to lead clinical investigator, Dr. David E. Toomey, who has orchestrated a multitude of clinical trials for some of the top pharmaceutical manufacturers in the United States, "Over a twelve week period, 120 study participants who were overweight participated in the study. The Burner Balm group lost an average of 7 to 9 pounds versus the placebo group who lost an average of 1.43 to 1.64 pounds in the 12 week period.

17 Jul 2010

Aetna awards $75,000 grant to support Judge Glenda Hatchett's ParentPowerNow! anti-obesity program

Aetna announced today it will support Judge Glenda Hatchett's ParentPowerNow! anti-obesity program. "Parent Power Now!" is an online community of people interested in working together and learning more about parenting. Aetna has awarded a $75,000 grant and will provide health content for the ParentPowerNow! website, guest speakers to address healthy living on Judge Hatchett's live website radio program, and support for health events scheduled around the country.

17 Jul 2010

Gluten free diet reduces inflammation, improves digestion

In 2008, the Garmin-Transitions US Cycling Team experimented with a gluten free diet as a way to improve performance by reducing inflammation, which is important for weeks-long races. The experiment was a success.

17 Jul 2010

Epizyme publishes two new review papers on epigenetics

Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme classes, as well as chemical biology approaches for discovering small molecule inhibitors of these epigenetic enzymes, and demonstrate Epizyme's scientific leadership in the area of epigenetics.

17 Jul 2010

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.

17 Jul 2010

Amgen granted FDA priority review designation for denosumab BLA

Amgen today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.

17 Jul 2010

Researchers discover potential way to stop tumor growth

Washington State University researchers have discovered a way to help cancer cells age and die, creating a promising avenue for slowing and even stopping the growth of tumors. "Hopefully, we can make cancer cells die like normal cells," says Weihang Chai, an assistant professor in the WSU School of Molecular Biosciences and WWAMI medical education program in Spokane. "Basically, you make the cancer cell go from immortal to mortal."

17 Jul 2010

Impact of circadian dysregulation on mental, physical health

Circadian (daily) rhythms are found in all functions - e.g. performance, mood, endocrine rhythms, behaviour, sleep timing. The biological clocks that control circadian rhythms are based on a genetic programme of interacting molecules in cells throughout the body, coordinated by a ´master clock´ in the brain and synchronised by external cues, mainly light.

16 Jul 2010

Largest effort to find gene-environment interactions underlying schizophrenia risk

At the 23rd ECNP Congress 2010 in Amsterdam, Professor Dr. Jim van Os, Chairman of the Department of Psychiatry and Neuropsychology at Maastricht University Medical Centre, The Netherlands, will present the EU-GEI project, involving more than 7,500 patients and their families, which brings together a multidisciplinary research team from 15 countries in the largest effort to date to find gene-environment interactions underlying schizophrenia risk.

16 Jul 2010

Report identifies gaps in research for 20 suspected carcinogens

A new report from the American Cancer Society and other world-leading health groups identifies gaps in research for 20 suspected carcinogens whose potential to cause cancer is as yet unresolved. The report is designed to prioritize agents for additional research, and to lead to well-planned epidemiologic or mechanistic studies leading to more definitive classification of these agents.

16 Jul 2010

National Trauma Institute launches 'Stop the Bleeding' awareness and giving campaign

The National Trauma Institute (NTI), a non-profit organization dedicated to funding trauma research in the United States, launched a powerful awareness and giving campaign in the heart of New York City today. While the images in the 15-second message may disturb some, trauma surgeon and NTI chairperson Dr. Timothy Fabian said, "We can't ignore the bloody truth—traumatic injury kills more than 170,000 people each year, not counting our soldiers overseas. Action is needed."

16 Jul 2010

Joint statement to help patients, physicians make informed decisions about use of rosiglitazone

The Endocrine Society, American Diabetes Association and American Association of Clinical Endocrinologists issue joint statement in response to an FDA panel's recommendation to keep rosiglitazone (Avandia) on the market

16 Jul 2010

Treatment admissions for abuse of prescription pain relievers increases by over 400%: Study

The proportion of all substance abuse treatment admissions of those aged 12 and older involving abuse of prescription pain relievers rose by over 400 percent from 2.2 percent in 1998 to 9.8 percent in 2008 according to a new study be the Substance Abuse and Mental Health Services Administration (SAMHSA). This dramatic rise in the proportion of admissions associated with the abuse of these drugs occurred among nearly all segments of the population regardless of age, gender, educational level and employment status.

16 Jul 2010

Active family engagement is important for recovery from substance abuse, chemical dependency

Active family engagement and commitment is one of the most underappreciated aspects of recovery from substance abuse and chemical dependency, according to clinical staff at Timberline Knolls Residential Treatment Center, a leading eating disorder and addiction treatment center.

16 Jul 2010

Medical Condition News

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

AMPK may regulate epigenetic mechanism: Research

Proton therapy treatment for anal canal cancer performed for first time in US

Ingen files patent to produce new drug insulin thermos product

Resveratrol concentration impacts cancer risk mitigation: Study

Pacific Shore releases clinical trial results for Burner Balm lip balm

Aetna awards $75,000 grant to support Judge Glenda Hatchett's ParentPowerNow! anti-obesity program

Gluten free diet reduces inflammation, improves digestion

Epizyme publishes two new review papers on epigenetics

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Amgen granted FDA priority review designation for denosumab BLA

Researchers discover potential way to stop tumor growth

Impact of circadian dysregulation on mental, physical health

Largest effort to find gene-environment interactions underlying schizophrenia risk

Report identifies gaps in research for 20 suspected carcinogens

National Trauma Institute launches 'Stop the Bleeding' awareness and giving campaign

Joint statement to help patients, physicians make informed decisions about use of rosiglitazone

Treatment admissions for abuse of prescription pain relievers increases by over 400%: Study

Active family engagement is important for recovery from substance abuse, chemical dependency

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News